## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# **Review Proposal Project**

NICE Technology Appraisal No. 238; Tocilizumab for the treatment of systemic juvenile idiopathic arthritis, and No.302; Canakinumab for treating systemic juvenile idiopathic arthritis

#### Provisional matrix of consultees and commentators

Consultees		Commentators (no right to submit or appeal)		
Manufacturers/sponsors		G	General	
•	Novartis (canakinumab)	•	Allied Health Professionals Federation	
•	Roche Products (tocilizumab)	•	Board of Community Health Councils in Wales	
Pa	tient/carer groups	•	British National Formulary	
•	Action For Sick Children	•	Care Quality Commission	
•	Action on Pain	•	Department of Health, Social Services	
•	Afiya Trust		and Public Safety for Northern Ireland	
•	Arthritis Action	•	Healthcare Improvement Scotland	
•	Arthritis and Musculoskeletal Alliance	•	Medicines and Healthcare Products	
•	Arthritis Care		Regulatory Agency	
•	Black Health Agency	•	National Association of Primary Care	
•	Children's Arthritis Trust	•	National Pharmacy Association	
•	Children's Chronic Arthritis	•	NHS Alliance	
	Association	•	NHS Commercial Medicines Unit	
•	Children's Society	•	NHS Confederation	
•	Disability Rights UK	•	Scottish Medicines Consortium	
•	Equalities National Council			
•	Leonard Cheshire Disability	<u>C</u> c	omparator manufacturers	
•	Muslim Council of Britain	•	AbbVie Ltd (adalimumab)	
•	Muslim Health Network	•	Hameln Pharmaceuticals	
•	National Children's Bureau		(methotrexate)	
•	National Rheumatoid Arthritis Society	•	Hospira (methorexate)	
•	Pain Concern	•	Medac (methotrexate)	
•	Pain Relief Foundation	•	Merck Sharp & Dohme (infliximab)	
•	Pain UK	•	Mercury Pharma Group (methotrexate)	
•	South Asian Health Foundation	•	Orion Pharma UK (methotrexate)	
•	Specialised Healthcare Alliance	•	Pfizer (etanercept, methotrexate)	
•	WellChild	•	Sandoz (methotrexate)	
		•	Sigma Pharmaceuticals (methotrexate)	
Professional groups		•	Swedish Orphan Biovitrum Ltd	
•	British Association of Occupational		(anakinra)	
	Therapists and College of	•	Teva UK (methotrexate)	
	Occupational Therapists	•	Wockhardt UK (methotrexate)	
•	British Geriatrics Society	_	de la descripción de la constante de la consta	
•	British Health Professionals in	Re	elevant research groups	

NICE Technology Appraisal No. 238; Tocilizumab for the treatment of systemic juvenile idiopathic arthritis, and No.302; Canakinumab for treating systemic juvenile idiopathic arthritis

Issue date: January 2015

Page 1 of 2

# Rheumatology

- British Institute of Musculoskeletal Medicine
- British Orthopaedic Association
- British Paediatric Rheumatology Group
- British Pain Society
- British Society for Paediatric and Adolescent Rheumatology
- British Society for Rheumatology
- British Society of Rehabilitation Medicine
- Physiotherapy Pain Association
- Primary Care Rheumatology Society
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Paediatrics and Child Health
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- United Kingdom Clinical Pharmacy Association

#### Others

- Department of Health
- NHS Canterbury and Coastal CCG
- NHS England
- NHS High Weald Lewes Havens CCG
- Welsh Government

- Arthritis Research UK
- Bone Research Society
- Chronic Pain Policy Coalition
- Cochrane Musculoskeletal Group
- MRC Clinical Trials Unit
- National Institute for Health Research

#### Assessment Group

- Assessment Group tbc
- National Institute for Health Research Health Technology Assessment Programme

## Associated Guideline Groups

- National Clinical Guideline Centre
- National Collaborating Centre for Women's and Children's Health

## Associated Public Health Groups

- Public Health England
- Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

### PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

#### **Definitions:**

### **Consultees**

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD). All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

# Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.